Notably, FLAURA is a multicenter phase III study which aimed to assess both the safety and efficacy of osimertinib in previously untreated advanced NSCLC patients with activating mutations of the EGFR gene [62]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.